Navigation Links
EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
Date:12/13/2010

HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment.  The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions.  The University of Alabama at Birmingham (UAB) Hospital is the first member institution to open enrollment. Dr. Ronald Alvarez, of UAB Hospital, is the Study Chair for the trial. The GOG Principal Investigator at UAB Hospital is Dr. Mack Barnes.  

"This is a significant milestone and accomplishment for the company," commented Dr. Khursheed Anwer, President and CSO of EGEN. "We are pleased to have this trial begin as it advances our novel EGEN-001 product in the clinic for the treatment of recurrent ovarian cancer.  The product utilizes the Company's proprietary TheraPlas® delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply.  We expect a number of the leading cancer centers in the U.S. to participate in this study and planning is underway to initiate additional Phase II trials in 2011, including the evaluation of EGEN-001 in treatment of colorectal cancer patients."

About Ovarian Cancer

Ovarian cancer represents the fifth most common form of cancer affecting women and is the most lethal of gynecological malignancies, ranking fourth in cancer deaths among women. The death rate for this disease has not changed much in the last 50 years.  This cancer is often diagnosed at an advanced stage after the cancer has spread beyond the ovary. Over $2 billion is spent in the U. S. each year on treatment of ovarian cancer.<
'/>"/>

SOURCE EGEN, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... und MARSEILLE , Frankreich, ... , Weltweite Exklusivlizenz der Universität ... die Entwicklung von Tests auf SF3B1-Mutationen, einschließlich ... Neuer Test weist Mutationen des SF3B1-Gens ... Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NasdaqGS: ABAX ), a medical products ... results for the first fiscal quarter ended June 30, ... of $47.5 million, up 10% over last year,s comparable ... over last year,s comparable quarter. Revenues highlights: ... 20% over last year,s comparable quarter. , Veterinary ...
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... The report, “Glass Fiber & Glass Fiber Reinforced ... Manufacturing Process, By Application (Transportation, Construction, Electrical & ... Trends & Forecast to 2019”, defines and segments ... and forecast by value and volume. , Browse ... through 347 slides and in-depth TOC on "GFRP ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... TUCSON, Ariz., Nov. 25 ... announced that its LogistiCare subsidiary, the nation,s largest coordinator ... award from the State of Florida Commission for the ... both Miami-Dade and Volusia Counties. The award, estimated ...
... , - Agreement Provides Financial Flexibility, Allowing ... Quebec, Nov. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... standby equity distribution agreement (SEDA) with YA Global Master SPV ... terms of the agreement, YA has committed to provide up ...
... and other greenhouse emissions will have major direct health ... change, especially in low-income countries, according to a series ... the British journal The Lancet . Two ... Kirk R. Smith, professor of global environmental health, and ...
... ... sinusitis. A clinically proven, minimally invasive technology for treating chronic sinus inflammation is available ... a small catheter and balloon to quickly open and expand blocked sinuses. , ... (Vocus) November 25, 2009 ...
... ... be offering $100 off every memory foam and latex sofa bed mattress + an additional ... code “BLACKFRIDAY” in the shopping cart to take advantage of this special offer. , ... (PRWEB) November 25, 2009 -- Millions ...
... ... your Emergency Department,s management of seasonal and pandemic novel H1N1 influenza cases this season? ... Which - if any - antiviral should you prescribe? EB Medicine announces its November ... resources on influenza diagnosis and treatment. , ...
Cached Medicine News:Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 2Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 3
... first manufacturer to offer through-the-lens (TTL) ... These next generation loupes feature extremely ... design, and are multi-coated lens for ... SheerVision's proprietary SureFit system - you ...
Easy pull-on garment's feature Rainey's exclusive Non-Slip Dome™design and adjustable Velcro© closure at neck for optimal comfort and support. Choose covered or non covered ear design....
Facial Wrap...
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Medicine Products: